linjc16/ctgov huggingface dataset:
Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the clinical efficacy of maintenance on low and high doses of buprenorphine with methadone for cocaine abusing opiate addicts.

Official Title
-----------------
Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts

Conditions
-----------------
Cocaine-Related Disorders, Opioid-Related Disorders, Substance-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depression |  |  | 
| Withdrawal symptoms |  |  | 
| Opioid and cocaine use |  |  | 
| Social and psychological functioning |  |  | 
| AIDS risk behavior |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Opioid-Related Disorders
Treatment of Primary Menstrual Pain With Kanion Capsule

Study Overview
=================
Brief Summary
-----------------
The objectives of this clinical trial are: To further study the safety of Kanion Capsule (GF) in primary dysmenorrhea subjects; To further evaluate the efficacy of GF in treatment of primary dysmenorrhea.

Official Title
-----------------
Treatment of Primary Dysmenorrhea With Kanion Capsule (GF) A Randomized, Double-blind, Placebo-controlled, Repeated-Dose and Multi-Center Clinical Phase II Trial

Conditions
-----------------
Primary Dysmenorrhea

Intervention / Treatment
-----------------
* Drug: Kanion Capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primary dysmenorrhea Exclusion Criteria: secondary dysmenorrhea

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Kanion Capsule|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain reduction |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| accompanying symptoms improvement |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary dysmenorrhea, Herbal remedy
Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

Study Overview
=================
Brief Summary
-----------------
This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. The study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. We may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.

Detailed Description
-----------------
This is an open label study to determine the effects of the administration of Interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. The study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. We may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.

Official Title
-----------------
Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma

Conditions
-----------------
Healthy, Mycobacterium Infections, Atypical

Intervention / Treatment
-----------------
* Drug: interferon gamma


Participation Criteria
=================
Eligibility Criteria
-----------------
Demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary. Received medical treatment for at least 3 months without improvement. Preserved renal, hepatic and hematologic function. Negative pregnancy urine and effective contraceptive. Age range greater than 5. No secondary immunodeficiency such as HIV or malignancy. Not currently receiving cytotoxic therapy within the past 3 months. Not pregnant or lactating. No seizure disorders. No known symptomatic cardiac disease.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: interferon gamma|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immune Adjuvant, Phagocytes, Non-tuberculous Mycobacterial Infection
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Study Overview
=================
Brief Summary
-----------------
This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice. The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.

Official Title
-----------------
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least one measurable lesion according to RECIST criteria Histologically or cytologically confirmed NSCLC of adeno histology Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |
| 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS of the third-line therapy |  | 9 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall objective tumor response (complete response [CR] + partial response [PR]) of the third-line therapy by RECIST criteria |  | 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EGFR-TKI therapy, NSCLC, Efficacy
Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey

Study Overview
=================
Brief Summary
-----------------
a brief questionnaire to get a clearer picture of the situation regarding surgical patients with special emphasis on asymptomatic Covid-19 patients.

Detailed Description
-----------------
With new evidence on the role of asymptomatic patients in spreading the disease during the Covid-19 pandemic, symptom driven guidelines for testing, hospital allocation and personal protective equipment (PPE) use do not seem appropriate to limit in-hospital transmission. At time when lockdowns are in place in most countries, hospitals can become the new source of infection. Guidelines are very variable depending on local policies and availability of medical supplies, resulting in most hospitals taking different preventive measures.

Official Title
-----------------
Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey

Conditions
-----------------
Surgery, COVID, Asymptomatic Patient, Covid-19, Preventive Measures

Intervention / Treatment
-----------------
* Other: global survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: general surgeon Exclusion Criteria: other speciality
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: global survey|surgery questionnaire|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overview of surgical management on preventive measures of hospital infection spread during covid 19 |  | 2/04/2020 to 15/04/2020 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| testing policies and preventive measures for Covid-19, and their association with asymptomatic cases. |  | 02/04/2020 to 15/04/2020 |
Exercise in Patients With a Biventricular Pacemaker

Study Overview
=================
Brief Summary
-----------------
The investigators will evaluate the effects of an exercise program (walking on a treadmill) on the physical performance, the cardiorespiratory function, the proclivity to heart arrhythmias and the quality of life of patients with severely impaired left ventricular function and a bi-ventricular resynchronization pacemaker.

Official Title
-----------------
Effects of an Exercise Program on the Tendance to Severe Arrhythmias in Patients With Severely Impaired Left Ventricular Function and Cardial Re-synchronisation Therapy

Conditions
-----------------
Left Ventricular Failure

Intervention / Treatment
-----------------
* Other: Endurance exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Left ventricular failure Resynchronization therapy with a biventricular pacemaker Ability to understand written German Exclusion Criteria: Age over 75 years Severe cardiac arrhythmia All conditions which can be aggravated by an exercise program

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: Intervention<br>The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max. | Other: Endurance exercise<br>* The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal oxygen uptake (VO2max) |  | At recruitment and after 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body mass index (BMI) |  | At recruitment and after 12 weeks | 
| Brain natriuretic peptide (BNP) |  | At recruitment and after 12 weeks | 
| Body composition |  | At recruitment and after 12 weeks | 
| Mood |  | At recruitment and after 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Left ventricular failure, chronic heart failure, Pacemaker, Resynchronisation therapy, Exercise, Endurance exercise
The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study

Study Overview
=================
Brief Summary
-----------------
This cross-sectional study, conducted at the Sindh Institute of Urology and Transplantation (SIUT), involved a retrospective data review of all the patients diagnosed with breast cancer from March 2017 to December 2021. The demographic characteristics, clinical presentation, stage of the disease, and histopathological characteristics were analyzed.

Official Title
-----------------
The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study

Conditions
-----------------
Breast Cancer, Breast Neoplasms, Breast Cancer Invasive, Breast Cancer Stage, Breast Cancer Metastatic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients diagnosed with breast cancer Exclusion Criteria: The patients that were lost to follow-up after the first consultation and those consulting for a second opinion were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with breast cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic characteristics of patients with breast cancer | age, gender, residence, marital status | At the time of presentation | 
| Risk factors of patients with breast cancer | age at menarche, menopause, parity, breastfeeding, contraception, family history, body mass index | At the time of presentation | 
| Clinical presentation of patients with breast cancer | site and duration | At the time of presentation | 
| Stage of the breast cancer | American Joint Committee on Cancer (AJCC) Anatomic Stage Groups for breast cancer | At the time of presentation | 
| Histopathological characteristics of patients with breast cancer | tumor type, hormone receptor status, Ki-67, and grade | At the time of presentation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, Clinical audit, Breast cancer risk factors, Breast cancer screening, Clinicopathological characterisitics
Prevention Recurrent Otitis Media in the Young Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out if young children have more benefit of the combination of adenotomy and tympanostomy than plain tympanostomy in prevention of recurrent otitis media.

Detailed Description
-----------------
Recurrent otitis media is the most common bacterial disease in young children. Many risk factors are known, but benefit of operations are conflicting in children under two years of age. In this randomized prospective controlled trial, the effect of tympanostomy tubes is compared to the effect of the combination of adenotomy and tympanostomy tubes in preventing recurrent otitis media. A control group with no active treatment is also included. The speed of recovery is studied by recording the daily symptoms and number of days of effusion comparing the differences between the groups. Life quality issues are recorded preoperatively and at about four and twelve months after the operation and are compared between the groups and to healthy children of the same age.

Official Title
-----------------
Effect of Adenotomy and Tympanostomy on Preventing Recurrent Otitis Media in the Young Children

Conditions
-----------------
Otitis Media

Intervention / Treatment
-----------------
* Procedure: adenoidectomy and tymapanostomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 3 otitis media episodes during the last half year address near (< 50 km) the university hospital of Oulu Exclusion Criteria: otitis media effusion lasting longer than two months without acute exacerbations prior adenoidectomy or tympanostomy head or neck malformation retarded child serious disease chemoprophylaxis for another disease

Ages Eligible for Study
-----------------
Minimum Age: 10 Months
Maximum Age: 24 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: adenoidectomy and tymapanostomy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - number of acute otitis media |  |  | 
| - quality of life issues |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - time to first recurrence |  |  | 
| - speed of recovery of each otitis media |  |  | 
| - number of days of middle ear effusion |  |  | 
| - number of upper respiratory infections |  |  | 
| - prevention of otitis media caused by pnemococcus in carrier of pneumococcus |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent otitis media, adenoidectomy, tympanostomy, young children, prevention, quality of life
Smart Capnography Respiratory Index in Post Anesthesia Patients

Study Overview
=================
Brief Summary
-----------------
The smart capnography respiratory index is a software tool that constitutes a representation of 4 parameters: End Tidal CO2, respiratory rate, O2 saturation and heart rate already displayed on a monitor in the form of a single respiratory index integer value ranging from 1 to 10 with trend information. The index is to be used to identify and display status and changes in patient respiratory status in a simple manner based on the summary of changes in the 4-above mentioned parameters. the respiratory index is to be used in varied clinical environments and is intended for use in adult and pediatric patients.

Official Title
-----------------
Smart Capnography Respiratory Index: Clinical Evaluation

Conditions
-----------------
Patients After Surgery and Anesthesia Monitored in the PACU

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult or pediatric patients after surgery and anesthesia, monitored in the PACU Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>intubated patients | |
| 2<br>non intubated patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To demonstrate that the displayed respiratory index values and their associated description match the clinical status of the patients |  | 3 months |
Natural History of Mineral Metabolism Parameters and Protein-bound Toxins in Incident Peritoneal Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
The aims of this study are To evaluate the natural history of plasma concentrations and renal and peritoneal clearances of small water-soluble uremic retention molecules (URM), 'middle molecules', and protein bound URM in incident peritoneal dialysis (PD) patients. To evaluate the natural history and determinants of the generation rate of URM originating from bacterial protein fermentation in PD patients. To evaluate the natural history of biochemical parameters of mineral metabolism in incident PD patients.

Official Title
-----------------
Natural History of Biochemical Parameters of Mineral Metabolism and Protein-bound Uremic Retention Molecules in Incident Peritoneal Dialysis Patients: a Longitudinal Observational Study

Conditions
-----------------
Complication of Peritoneal Dialysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Incident PD patients, defined as patients who started on PD as first renal replacement therapy less than 8 weeks before inclusion written informed consent age > 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| natural history of clearances and serum parameters of mineral metabolism and protein-bound toxins | To evaluate the natural history of plasma concentrations and renal and peritoneal clearances of small water-soluble uremic retention molecules (URM), 'middle molecules, and protein bound URM in incident peritoneal dialysis (PD) patients. | 15 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| determinants of generation rate of uremic retention solutes | To evaluate the natural history and determinants of the generation rate of URM originating from bacterial protein fermentation in PD patients. | 15 years on average | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biochemical parameters, mineral metabolism, protein-bound uremic retention solutes, incident PD patients